10-Q: Enhabit Swings to Profit, Cuts Debt Amid Regulatory Headwinds

Enhabit, Inc. reported a significant turnaround to net income profitability and reduced debt in Q2 2025, despite facing a proposed 6.4% cut in 2026 Medicare home health payments.

Summary

• Net income attributable to Enhabit, Inc. was $5.2 million for Q2 2025, a significant improvement from a $0.2 million loss in Q2 2024.
• For the six months ended June 30, 2025, net income attributable to Enhabit, Inc. was $23.0 million, up from $0.0 million in the prior year period.
• Total net service revenue increased by 2.1% to $266.1 million for Q2 2025, and by 0.6% to $526.0 million for the six months ended June 30, 2025.
• Hospice segment revenue grew significantly by 19.4% in Q2 2025 and 20.0% for the six months, driven by a 12.3% increase in average daily census and improved unit revenue per patient day.
• Home Health segment revenue decreased by 2.0% in Q2 2025 and 4.0% for the six months, primarily related to a 2.5% decrease in unit revenue per patient day due to growth in non-Medicare patients.
• Operating income increased by 49.1% to $16.7 million for Q2 2025 and by 35.3% to $32.6 million for the six months.
• Adjusted EBITDA increased by 6.7% to $26.9 million for Q2 2025 and by 5.9% to $53.5 million for the six months.
• The company successfully exited its Credit Agreement Covenant Adjustment Period on May 9, 2025, by achieving a Total Net Leverage Ratio below 4.50 to 1.00 for the quarter ended March 31, 2025.
• Long-term debt, net of current portion, decreased to $456.9 million as of June 30, 2025, from $492.6 million at December 31, 2024.
• A gain of $19.3 million was recorded from the sale of an investment in Medalogix/TVG Holdings, LLC, with $20.0 million of proceeds used to reduce debt.
• The Centers for Medicare and Medicaid Services (CMS) proposed a 6.4% estimated decrease to home health payments for fiscal year 2026, effective January 1, 2026.
• CMS issued a final rule for hospice payments for fiscal year 2026, implementing a net increase of 2.6% effective October 1, 2025.
• Seven Home Health and four Hospice branches were closed or consolidated in the first half of 2025 due to performance.

Sentiment

Score: 6

Explanation: The company demonstrated a strong financial turnaround with significant net income and operating income growth, successful debt reduction, and improved Hospice segment performance. However, the proposed substantial cuts to Medicare home health payments for 2026 introduce significant future uncertainty and risk, tempering overall positive sentiment despite current operational improvements.

Positives

• Achieved net income of $5.2 million in Q2 2025, a significant turnaround from a $0.2 million loss in Q2 2024.
• Reported $23.0 million in net income for the six months ended June 30, 2025, compared to $0.0 million in the prior year period.
• Operating income increased by 49.1% in Q2 2025 and 35.3% for the six months, demonstrating improved operational efficiency.
• Adjusted EBITDA grew by 6.7% in Q2 2025 and 5.9% for the six months, indicating stronger core business performance.
• Successfully exited the Credit Agreement Covenant Adjustment Period on May 9, 2025, by meeting the Total Net Leverage Ratio requirement, providing improved pricing and operational flexibility.
• Reduced long-term debt by $35.7 million from December 31, 2024, to June 30, 2025, improving the balance sheet.
• Realized a $19.3 million gain from the sale of an investment in Medalogix/TVG Holdings, LLC, with $20.0 million of proceeds used for debt reduction.
• Hospice segment revenue increased by 19.4% in Q2 2025 and 20.0% for the six months, driven by strong growth in average daily census (12.3%) and improved unit revenue per patient day.
• CMS finalized a 2.6% net increase in hospice payments for fiscal year 2026, effective October 1, 2025.
• Improved clinical staff productivity contributed to a 1.4% decline in Home Health unit cost per patient day for the six months ended June 30, 2025.

Negatives

• Home Health segment net service revenue decreased by 2.0% in Q2 2025 and 4.0% for the six months, primarily due to a 2.5% decrease in unit revenue per patient day.
• Home Health average daily census decreased by 3.4% in Q2 2025 and 5.4% for the six months for Medicare patients.
• Home Health visits decreased by 5.2% in Q2 2025 and 7.3% for the six months.
• Cost per visit in Home Health increased by 6.4% in Q2 2025 and 5.0% for the six months.
• The proposed 6.4% estimated decrease in 2026 Medicare home health payments, if finalized, could significantly reduce reimbursement rates for the industry.
• Seven Home Health and four Hospice branches were closed or consolidated in the first half of 2025 due to performance issues.
• Ongoing legal fees for specific lawsuits are noted as 'unusual or nonrecurring items'.

Risks

• Ability to execute on strategic plans.
• Regulatory and other developments impacting the markets for services, particularly changes in Medicare reimbursement rates.
• General economic conditions.
• Changes in the episodic versus non-episodic mix of payers, patient case mix, and payment methodologies.
• Ability to attract and retain key management personnel and healthcare professionals.
• Potential disruptions or breaches of information systems (company, vendors, payers, contract counterparties).
• Outcome of litigation, including potential qui tam actions under the False Claims Act.
• Quality performance and ratings.
• Ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures.
• Ability to successfully integrate technology in operations.
• Ability to control costs, particularly labor and employee benefit costs, especially in an inflationary environment.
• Uncertainty regarding the ultimate impact of the proposed 2026 Home Health Rule, which could result in significant reduction in reimbursement rates.
• Non-compliance with financial covenants under credit facilities could lead to acceleration of debt maturity and foreclosure on collateral.

Future Outlook

Management expects the 2026 Hospice Final Rule to result in a 2.6% payment increase, in line with the market basket update. However, the proposed 6.4% decrease in 2026 Home Health payments, if finalized, is expected to significantly reduce reimbursement rates for the industry, and the company is actively engaged in advocacy efforts. Management is evaluating additional cost control and operating efficiency options, including advanced management of visits per episode, in response to the proposed Home Health cuts. The company forecasts continued compliance with its financial covenants through the next year.

Management Comments

• "We are actively engaged in advocacy efforts in response to the proposed 2026 Home Health Rule, which, if finalized as proposed, could result in a significant reduction in reimbursement rates for our industry."
• "As the ultimate impact of the proposed 2026 Home Health Rule remains uncertain, we continue to monitor developments."
• "Due to the severity of the proposed cuts in the 2026 Home Health Rule, management is evaluating additional options for further cost control and operating efficiencies, including among other things, advanced management of visits per episode."
• "Recruiting and retaining qualified personnel, including management, for our home health agencies and hospice provider locations remains a high priority for us."
• "Management continually evaluates the Company's expected compliance with the covenants described above and takes all appropriate steps to proactively renegotiate such covenants when appropriate."

Industry Context

The home health and hospice industry is highly regulated, with reimbursement rates heavily influenced by the Centers for Medicare and Medicaid Services (CMS). The proposed 6.4% cut to home health payments for 2026 represents a significant headwind for the entire sector, potentially impacting profitability and operational models across the board. In contrast, the finalized 2.6% increase for hospice payments offers a more stable outlook for that segment. The company's proactive cost control measures and advocacy efforts reflect the industry's broader response to evolving regulatory pressures and the need to adapt to changing reimbursement landscapes while managing labor costs in a competitive environment.

Corporate Governance

Legal Proceedings

• The company is routinely subject to various legal actions, proceedings, claims, and regulatory/governmental audits and investigations in the highly regulated healthcare industry.
• No pending legal proceedings are believed to be material as of June 30, 2025.
• The False Claims Act (FCA) allows private citizens (relators) to institute civil proceedings on behalf of the United States, which are common in the healthcare industry and can involve significant monetary damages, fines, and penalties.
• The company may be party to one or more undisclosed qui tam cases brought pursuant to the FCA.
• Unusual or nonrecurring items include third-party legal fees associated with the suit Enhabit, Inc. et al. v. Nautic Partners IX, L.P. et al., where the company asserted claims for breach of fiduciary duty, aiding and abetting, and usurpation of corporate opportunity arising from actions involving its former officers.

Related Party Transactions

• In connection with the Separation from Encompass Health Corporation on July 1, 2022, Enhabit entered into a Separation and Distribution Agreement, a Tax Matters Agreement, and an Employee Matters Agreement with Encompass.
• A Transition Services Agreement (TSA) with Encompass expired on March 31, 2024, after which Enhabit began performing functions using its own resources or third-party providers.
• The company sold its minority equity investment in TVG Holdings, LLC (which included Medalogix) for approximately $21 million on March 19, 2025, resulting in a $19.3 million gain. Medalogix was no longer a related party after this date.
• Costs incurred prior to the transaction date for Medalogix's analytics platforms were approximately $1.2 million for the six months ended June 30, 2025, and $1.2 million and $2.4 million for the three and six months ended June 30, 2024, respectively.

Stakeholder Impact

• Shareholders: Positive impact from significant net income turnaround, debt reduction, and improved operational efficiency. Potential negative impact from proposed Medicare home health payment cuts and associated uncertainty.
• Employees: Potential impact from cost control initiatives and branch closures (seven Home Health and four Hospice branches closed/consolidated). Ongoing efforts to recruit and retain high-quality personnel.
• Customers (Patients): Continued provision of Medicare-certified skilled home health and hospice services across 34 states. Potential impact on service availability or scope if proposed payment cuts lead to significant operational changes.
• Creditors: Positive impact from debt reduction and compliance with financial covenants, reducing credit risk.
• Suppliers: Ongoing contractual obligations for medical and durable medical equipment, and business/software licensing.

Next Steps

• Actively engaged in advocacy efforts in response to the proposed 2026 Home Health Rule.
• Evaluating additional options for further cost control and operating efficiencies, including advanced management of visits per episode, due to proposed Home Health cuts.
• Monitoring developments regarding the final 2026 Home Health Rule.
• Company expects to incur approximately $3.3 million of cash tax liability from the sale of investment, with a significant portion payable in future periods.
• Expects to spend approximately $4 to $5 million for maintenance capital expenditures during 2025.
• Continually evaluates expected compliance with financial covenants and takes appropriate steps to proactively renegotiate when appropriate.

Key Dates

Recommendation

While Enhabit, Inc. demonstrated a strong financial turnaround in Q2 2025, achieving net income profitability and reducing debt, the proposed 6.4% cut to 2026 Medicare home health payments introduces substantial regulatory risk and uncertainty. The company's operational improvements and proactive debt management are positive, but the potential impact of these cuts on future revenue and profitability for the Home Health segment, which constitutes the majority of its business, warrants a cautious 'hold' recommendation. Investors should monitor the outcome of advocacy efforts regarding the proposed rule and the company's ability to mitigate its effects through cost controls and efficiency gains.

Keywords

Home Health, Hospice, Medicare, Healthcare Services, SEC Filing, Financial Results, Q2 2025, Enhabit, EHAB, Reimbursement Rates, Debt Reduction, Profitability, Regulatory Risk, CMS